Previous 10 | Next 10 |
OLDWICK, N.J. , June 9, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that results from the National Institutes of Health (NIH)-sponsored "At-Risk" Study...
Provention Bio (NASDAQ: PRVB ): Q1 GAAP EPS of -$0.29. More news on: Provention Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
OLDWICK, N.J. , May 8, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2019 and provided a ...
OLDWICK, N.J. , May 8, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced preliminary top-line results from its Phase 1b PULSE study which evaluated ...
Gainers: Roan Resources (NYSE: ROAN ) +41% . Alterity Therapeutics (NASDAQ: ATHE ) +32% . Changyou.com (NASDAQ: CYOU ) +22% . Sohu.com (NASDAQ: SOHU ) +19% . Enlivex Therapeutics (NASDAQ: ENLV ) +19% . Gardner Denver Holdings (NYSE: GDI ) +16% . Provention Bio (NASDAQ: PRVB ) ...
OLDWICK, N.J. , April 24, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has completed the enrollment in its Phase 2a PRINCE (PRovention In...
Gainers: ATA (NASDAQ: ATAI ) +97% . Provention Bio (NASDAQ: PRVB ) +29% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +24% . Chimerix (NASDAQ: CMRX ) +22% . FARO Technologies (NASDAQ: FARO ) +17% . Soliton (NASDAQ: SOLY ) +15% . GEE Group (NYSEMKT: JOB ) +14% . Geron (NASDAQ: GERN ) ...
Dosing is underway in a Phase 3 clinical trial, PROTECT , evaluating Provention Bio's (NASDAQ: PRVB ) PRV-031 (teplizumab) in patients with recent-onset type 1 diabetes (T1D). More news on: Provention Bio, Inc., Healthcare stocks news, Read more ...
OLDWICK, N.J. , April 9, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has dosed the first patient in its Phase 3 PROTECT clinical trial o...
OLDWICK, N.J. , April 2, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Douglas Jacobstein , M.D., as Vice President of Clinica...
News, Short Squeeze, Breakout and More Instantly...
Provention Bio, Inc. (NASDAQ: PRVB) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 3.14% on the day to $24.99. Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and comme...
2023-04-06 11:29:16 ET What Are Penny Stocks? The market for penny stocks has continued growing over the last few years. But what are these stocks in the first place? The general definition of penny stocks includes shares of companies trading below $5. Making money with penny st...
NEW YORK, NY / ACCESSWIRE / March 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seagen Inc. (NASDAQ:SGEN)'s sale t...